Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...

Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance ...

A groundbreaking study led by the Mayo Clinic Comprehensive Cancer Center has significantly deepened our understanding of ...

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

Thanks to a recent expansion of the Fred Hutch Nurse Navigation Program, newly referred cancer patients have more help than ...

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words ...

Adding serial circulating tumor DNA (ctDNA) assays to standard of care imaging surveillance had limited clinical benefits in ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the ...

Developed at the University of Michigan, MyHPVscore is a highly accurate blood test that can detect human papilloma virus-related head and neck cancer by measuring fragments of tumor DNA in a ...

Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.